Medical Device

Biomerica (Nasdaq:BMRA) announced today that the Korean Intellectual Property Office (KIPO) has issued a Notice of Allowance for a patent application covering Biomerica’s compositions, devices and methods of IBS sensitivity testing. The patent is expected to issue before September 2018. As quoted in the press release: The patent application specifically applies to Biomerica’s InFoods® IBS …

Biomerica (Nasdaq:BMRA) announced today that the Korean Intellectual Property Office (KIPO) has issued a Notice of Allowance for a patent application covering Biomerica’s compositions, devices and methods of IBS sensitivity testing. The patent is expected to issue before September 2018.

As quoted in the press release:

The patent application specifically applies to Biomerica’s InFoods® IBS product, which is currently in a clinical study in the U.S.  This patent would be the first for the InFoods® patent portfolio, providing patent protection for InFoods® IBS in Korea until 2035.

It is estimated that over 45 million Americans are affected by Irritable Bowel Syndrome (IBS).  The total cost (direct + indirect) of IBS has been estimated at $30 billion annually in the United States. IBS is a common condition that can substantially impair patient well-being and a person’s ability to function both at home and in the workplace.

Click here to read the full press release.

Featured

MARKETS

Markets
TSX20029.00-152.92
TSXV695.26-10.32
DOW30845.39-407.74
S&P 5003841.56-59.23
NASD11151.16-237.34
ASX7064.50-118.20

COMMODITIES

Commodities
Gold1843.17+0.99
Silver21.72-0.18
Copper4.280.00
Palladium1966.00-38.00
Platinum954.00-5.00
Oil113.54+1.33
Heating Oil3.66-0.01
Natural Gas8.15-0.15

DOWNLOAD FREE REPORTS

×